In addition, under the anti-PD-1 treatment in addition to the anti-VEGFR-2, CD4+ T cells in HCC normalized vessel formation, which might be helpful for the anti-tumor effect of this regimen [78]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.